tetano
Editor, Senior Moderator
Proc Natl Acad Sci U S A. 2018 Oct 23. pii: 201811345. doi: 10.1073/pnas.1811345115. [Epub ahead of print]
[h=1]The mechanism of resistance to favipiravir in influenza.[/h] Goldhill DH[SUP]1,[/SUP][SUP]2[/SUP], Te Velthuis AJW[SUP]3[/SUP], Fletcher RA[SUP]2[/SUP], Langat P[SUP]2[/SUP], Zambon M[SUP]1[/SUP], Lackenby A[SUP]1[/SUP], Barclay WS[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. While emergence of resistance has been observed for many antiinfluenza drugs, to date, clinical trials and laboratory studies of favipiravir have not yielded resistant viruses. Here we show evolution of resistance to favipiravir in the pandemic H1N1 influenza A virus in a laboratory setting. We found that two mutations were required for robust resistance to favipiravir. We demonstrate that a K229R mutation in motif F of the PB1 subunit of the influenza virus RNA-dependent RNA polymerase (RdRP) confers resistance to favipiravir in vitro and in cell culture. This mutation has a cost to viral fitness, but fitness can be restored by a P653L mutation in the PA subunit of the polymerase. K229R also conferred favipiravir resistance to RNA polymerases of other influenza A virus strains, and its location within a highly conserved structural feature of the RdRP suggests that other RNA viruses might also acquire resistance through mutations in motif F. The mutations identified here could be used to screen influenza virus-infected patients treated with favipiravir for the emergence of resistance.
[h=4]KEYWORDS:[/h] antiviral; influenza; polymerase; resistance; virus
PMID: 30352857 DOI: 10.1073/pnas.1811345115
Free full text
[h=1]The mechanism of resistance to favipiravir in influenza.[/h] Goldhill DH[SUP]1,[/SUP][SUP]2[/SUP], Te Velthuis AJW[SUP]3[/SUP], Fletcher RA[SUP]2[/SUP], Langat P[SUP]2[/SUP], Zambon M[SUP]1[/SUP], Lackenby A[SUP]1[/SUP], Barclay WS[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. While emergence of resistance has been observed for many antiinfluenza drugs, to date, clinical trials and laboratory studies of favipiravir have not yielded resistant viruses. Here we show evolution of resistance to favipiravir in the pandemic H1N1 influenza A virus in a laboratory setting. We found that two mutations were required for robust resistance to favipiravir. We demonstrate that a K229R mutation in motif F of the PB1 subunit of the influenza virus RNA-dependent RNA polymerase (RdRP) confers resistance to favipiravir in vitro and in cell culture. This mutation has a cost to viral fitness, but fitness can be restored by a P653L mutation in the PA subunit of the polymerase. K229R also conferred favipiravir resistance to RNA polymerases of other influenza A virus strains, and its location within a highly conserved structural feature of the RdRP suggests that other RNA viruses might also acquire resistance through mutations in motif F. The mutations identified here could be used to screen influenza virus-infected patients treated with favipiravir for the emergence of resistance.
[h=4]KEYWORDS:[/h] antiviral; influenza; polymerase; resistance; virus
PMID: 30352857 DOI: 10.1073/pnas.1811345115
Free full text